Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Gary S. Friedman"'
Autor:
Arif Soonasra, Julián Panés, Millie D. Long, Rajiv Mundayat, Chinyu Su, Walter Reinisch, Bruce E. Sands, Chudy I. Nduaka, Gary Chan, Gary S. Friedman, Nervin Lawendy, Edward V. Loftus
Publikováno v:
Inflammatory Bowel Diseases
Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We present integrated analyses of nonmelanoma skin cancer (NMSC) incidence in the tofacitinib UC clinical program. Methods Nonmelan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fc588b9a1f45d2b84f12cf702e04395
http://europepmc.org/articles/PMC8804509
http://europepmc.org/articles/PMC8804509
Autor:
Leonardo Salese, Rajiv Mundayat, Chinyu Su, Gary S. Friedman, Nervin Lawendy, Kevin L. Winthrop, Gary Chan, Walter Reinisch, Chudy I. Nduaka, Edward V. Loftus, Andrew John Thorpe, Daniel C. Baumgart
Publikováno v:
Journal of Crohn's & Colitis
Background and Aims Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis. We report integrated analyses of infections in the Phase [P]2 and P3 OCTAVE programmes. Methods Three cohorts were analysed: Induction [
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7744bb9ab6fd07bfa4bec39ecc7c0753
https://doi.org/10.1093/ecco-jcc/jjaa233
https://doi.org/10.1093/ecco-jcc/jjaa233
Autor:
Jiangwei Zhang, Kelly A. Fader, Shashi K. Ramaiah, Gary S. Friedman, Ravi Thadhani, Elliott M. Antman, Joseph P. Menetski, Vishal S. Vaidya
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics
Faced with the health and economic consequences of the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the biomedical community came together to identify, diagnose, prevent, and treat the novel disease at breathtaking s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::478ff5ea5a12c86fe82000f20ca853b8
https://doi.org/10.1124/jpet.120.000204
https://doi.org/10.1124/jpet.120.000204
Autor:
Nicole Spear, Krista L. Lentine, Roslyn B. Mannon, Shukal Bala, Gary S. Friedman, Michael Abecassis, Peter Nickerson, Stephen R. Karpen, Inish O’Doherty, Randall E. Morris, Peter S. Heeger, David A. Axelrod, Alexandre Loupy, Minnie M. Sarwal, Barbara Murphy
Publikováno v:
American Journal of Transplantation. 20:1495-1502
On September 27-28, 2018 the Food and Drug Administration (FDA) and the Critical Path Institute's Transplant Therapeutics Consortium convened a public workshop titled "Evidence-Based Treatment Decisions in Transplantation: The Right Dose & Regimen fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::173a99b8040601abc795f212d7b77f7d
https://doi.org/10.1111/ajt.15833
https://doi.org/10.1111/ajt.15833
Publikováno v:
Seminars in Nephrology. 39:120-131
The kidney's role as a major route of metabolism and clearance of xenobiotics and its ability to concentrate the glomerular filtrate make it particularly vulnerable to drug-induced toxicity. Improving kidney safety is an active area of research and t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffa5bc83bda52183eeff79c052792c66
https://doi.org/10.1016/j.semnephrol.2018.12.002
https://doi.org/10.1016/j.semnephrol.2018.12.002
Autor:
Adam S. Cheifetz, E Maller, Chudy I. Nduaka, Peter D.R. Higgins, Wenjin Wang, Gary S. Friedman, Bruce E. Sands, Chinyu Su, Daniel Quirk
Publikováno v:
Journal of Crohn's & Colitis
In order to identify the practical implications for both health care practitioners and patients in understanding differences between the results of trials assessing therapies for ulcerative colitis [UC], we reviewed clinical trials of therapies for m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30e7bfdac420c41dd316e02e0958b4af
https://doi.org/10.1093/ecco-jcc/jjz038
https://doi.org/10.1093/ecco-jcc/jjz038
Autor:
Haiying Zhang, Daniel Quirk, Stephen B. Hanauer, Chinyu Su, Deborah A Woodworth, Walter Reinisch, Nervin Lawendy, Chudy I. Nduaka, Peter D.R. Higgins, Adam S. Cheifetz, Gary S. Friedman, Remo Panaccione, Silvio Danese
Publikováno v:
Clinical Gastroenterology and Hepatology. 17:139-147
Tofacitinib is an oral, small molecule inhibitor of JAK for the treatment of ulcerative colitis (UC). We evaluated the onset of symptom improvement in post-hoc analyses of data from 2 phase 3 trials of induction therapy with tofacitinib in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbee5d60f893d5aff7cf8baa99ef6f29
https://doi.org/10.1016/j.cgh.2018.07.009
https://doi.org/10.1016/j.cgh.2018.07.009
Autor:
Leonardo Salese, Gary S. Friedman, Nervin Lawendy, Mark T. Osterman, Haiying Zhang, Chinyu Su, Andrew John Thorpe, Daniel Quirk, Chudy I. Nduaka, Walter Reinisch, Jean-Frederic Colombel
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 20(1)
Background & Aims Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). The efficacy and safety of tofacitinib in patients with moderate to severe UC, up to 1 year, have been reported. We investig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a39fee7c5f21f02beaf5575c15bdae8e
https://pubmed.ncbi.nlm.nih.gov/33039585
https://pubmed.ncbi.nlm.nih.gov/33039585
Autor:
Chinyu Su, Walter Reinisch, Nervin Lawendy, Chudy I. Nduaka, Silvio Danese, Gary S. Friedman, Adam S. Cheifetz, Daniel Quirk, Peter D.R. Higgins, Stephen B. Hanauer, Remo Panaccione, Haiying Zhang, Deborah A Woodworth
Publikováno v:
Journal of Crohn's and Colitis. 12:S046-S048
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11eafebc29df278c981fe0fa1d3d2a1e
https://doi.org/10.1093/ecco-jcc/jjx180.061
https://doi.org/10.1093/ecco-jcc/jjx180.061
Autor:
Gary Chan, Thomas R. Jones, Julián Panés, Nervin Lawendy, Gary S. Friedman, Ron Pedersen, Bruce E. Sands, Michele Moscariello, Chinyu Su, William J. Sandborn, Geert R. D'Haens
Publikováno v:
Clinical gastroenterology and hepatology, 17(8), 1541-1550. W.B. Saunders Ltd
Background & Aims Tofacitinib is an oral, small-molecule inhibitor of JAK approved in several countries for the treatment of ulcerative colitis (UC). We report integrated safety analyses of tofacitinib-treated patients with moderate to severe UC. Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::561c4718b6ca80e095e38f1dac925982
https://pure.amc.nl/en/publications/safety-of-tofacitinib-for-treatment-of-ulcerative-colitis-based-on-44-years-of-data-from-global-clinical-trials(8d6988a1-706d-40cb-bee7-639629c9ea36).html
https://pure.amc.nl/en/publications/safety-of-tofacitinib-for-treatment-of-ulcerative-colitis-based-on-44-years-of-data-from-global-clinical-trials(8d6988a1-706d-40cb-bee7-639629c9ea36).html
